N. Jäkel

发表

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

D. Niederwieser, M. McMullin, C. Harrison, 2015, Experimental Hematology & Oncology.

Non syndromic childhood onset congenital sideroblastic anemia: A report of 13 patients identified with an ALAS2 or SLC25A38 mutation.

T. Leblanc, H. Manceau, K. Maloum, 2017, Blood cells, molecules & diseases.

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse

D. Niederwieser, M. Cross, C. Wickenhauser, 2013, Haematologica.

Genotype/phenotype correlations of childhood‐onset congenital sideroblastic anaemia in a European cohort

G. Leverger, T. Leblanc, B. Isidor, 2019, British journal of haematology.

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM).

M. Triggiani, J. Panse, H. Kluin-Nelemans, 2021, The Journal of investigative dermatology.

A non-randomised trial of an art therapy intervention for patients with haematological malignancies to support post-traumatic growth

D. Niederwieser, S. Singer, K. Geue, 2013, Journal of health psychology.

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients

E. Willscher, H. Al-Ali, C. Dierks, 2022, Blood cancer journal.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

D. Niederwieser, R. Rohrberg, R. Krahl, 2013, Journal of Cancer Research and Clinical Oncology.

Spontaneous Remission of Acute Myeloid Leukemia Relapse after Hematopoietic Cell Transplantation in a High-Risk Patient with 11q23/MLL Abnormality

D. Niederwieser, J. Edelmann, T. Ittel, 2008, Acta Haematologica.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15

D. Niederwieser, J. Edelmann, M. Cross, 2022, Bone Marrow Transplantation.

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

M. Triggiani, J. Panse, H. Kluin-Nelemans, 2020, Allergy.